BD Vaginal Panel and BD CTGCTV2
The right treatment, begins with the right diagnosis
- Overview
- Products & Accessories
- EIFU & Resources
BD Vaginal Panel and BD CTGCTV2 assays provide comprehensive, actionable results for vaginitis and the most prevalent non-viral STIs.1-4
Clinicians and laboratories are faced with increasing
challenges in managing workload and patient needs.
Vaginitis and Sexually Transmitted Infections (STIs) are complex conditions and identifying the root cause of a patient’s infection can help avoid repeat visits and complications from recurrent infections.5,6
-
Traditional diagnostics
are subjective and have low sensitivity5,6
-
More than 1 out of 4 women
with vaginitis symptoms have multiple infections, making accurate diagnosis and treatment challenging7
-
93% of patients
who were positive for 1 STI, were also positive for BV or VVC8
-
Similar symptoms exist
across infection types, making clinical diagnosis difficult5,6
-
4 out of 10 women
with vaginitis symptoms don’t receive appropriate diagnosis and treatment9
-
Untreated infections
can result in significant complications such as pregnancy complications, fertility issues, or increased risk of contracting other STIs5,6
Features and Benefits
BD Vaginal Panel
- Test for the 3 most common causes of vaginitis – BV, VVC, and TV - in a single assay
- Designed with a proprietary, microbiome-based algorithm for BV to detect the 5 most common infection causing bacteria
- Provides separate results for C. glabrata and C. krusei that may not respond to traditional treatments6
- Uses the highly sensitive NAAT technology for detection of TV
BD CTGCTV2
- Test for the 3 most common non-viral STIs – Chlamydia, Gonorrhea, and Trichomonas – in a single assay
- Goes one step further than other diagnostics in detecting TV in the same assay. TV causes more STIs than CT and GC combined
- Includes dual gene targets for GC, maximizing assay specificity
- Uses the highly sensitive and CDC recommended NAAT technology for both CT and TV detection
Adapt to patient needs with flexible testing from a wide variety of sample types
Co-test vaginitis and STI from a single vaginal swab
*Self-collected in a healthcare setting
**Extra Genital CT GC testing with the use of oropharyngeal and rectal swabs are available on BD COR™ only
BD Vaginal Panel and BD CTGCTV2 can be run on both BD COR™ and BD MAX™ Instruments
BD Diagnostic Solutions is Now Waters Advanced Diagnostics
BD Diagnostic Solutions and Biosciences have combined with Waters Corporation to create a life sciences and diagnostics leader driven by innovation and a relentless commitment to our customers.
As we begin our new journey as part of Waters, there will be no immediate changes in how we serve you. The way you order your products and services and how you process payment for them will not change. Your points of contact for sales, customer service, technical service and support or clinical services will remain the same.
Our collection of literature on industries and on our offerings gives you information you can use to continue striving for excellence.
We support the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.
The BD Learning Academy offers a centralized repository of BD product training, education, and the ability to connect courses to your LMS.
We promote clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
- BD MAX™ Vaginal Panel Package Insert P0258(02)
- BD Vaginal for BD COR™ System Package Insert L012454(02)
- BD CTGCTV2 for BD MAX™ System Package Insert P0237(01)
- BD CTGCTV2 (for use with BD COR™ System) Package Insert P0294(01)
- Brown H and Drexler M. Popul Health Manag. 2020;23(S1):S3–S12.
- Thompson A et al. Eur J Clin Microbiol Infect Dis. 2020;39(1):39–44.
- Gaydos CA et al. Obstet Gynecol. 2017;130(1):181–9.
- Van Der Pol B et al. Clin Infect Dis. 2019;68(3):375–81.
- Hillier SL et al. Clin Infect Dis. 2021;72(9):1538–43.
Disclaimer:
This business has been acquired by Waters Corporation (“Waters”). For products referenced on this page, the legal manufacturer remains Becton, Dickinson and Company or one of its affiliates or subsidiaries (“BD”) until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under the regulatory authority of BD. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary waters.com/bdtransaction.